BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36484282)

  • 1. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
    Ando-Matsuoka R; Yagi K; Takaoka M; Sakajiri Y; Shibata T; Sawada R; Maruo A; Miyata K; Aizawa F; Hamano H; Niimura T; Izawa-Ishizawa Y; Goda M; Sakaguchi S; Zamami Y; Yamanishi Y; Ishizawa K
    Drug Dev Res; 2023 Feb; 84(1):75-83. PubMed ID: 36484282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
    Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
    Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis.
    He HS; Li BY; Chen QT; Song CY; Shi J; Shi B
    Med Sci Monit; 2019 Feb; 25():1169-1176. PubMed ID: 30755541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
    Sugawara K; Koizumi S; Horikawa Y; Mimori N; Tsuji T; Ishii H; Fujimori S; Onochi K; Watanabe H; Iijima K
    J Gastroenterol; 2019 Nov; 54(11):963-971. PubMed ID: 31037448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis.
    Kang H; Kim BJ; Choi G; Kim JG
    Medicine (Baltimore); 2019 Jun; 98(24):e15860. PubMed ID: 31192917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
    Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
    Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
    Kagawa T; Iwamuro M; Ishikawa S; Ishida M; Kuraoka S; Sasaki K; Sakakihara I; Izumikawa K; Yamamoto K; Takahashi S; Tanaka S; Matsuura M; Hasui T; Wato M; Inaba T
    Aliment Pharmacol Ther; 2016 Sep; 44(6):583-91. PubMed ID: 27464849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
    Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
    Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
    Tsujita K; Deguchi H; Uda A; Sugano K
    J Cardiol; 2020 Jul; 76(1):51-57. PubMed ID: 32184027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
    Kambara H; Hosohata K; Nakatsuji T; Ueno S; Oyama S; Inada A; Niinomi I; Wakabayashi T; Iwanaga K
    Pharmazie; 2020 Oct; 75(10):527-530. PubMed ID: 33305731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study: Vonoprazan and proton pump inhibitors in
    Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
    World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis.
    Liu C; Feng BC; Zhang Y; Li LX; Zuo XL; Li YQ
    J Dig Dis; 2019 Oct; 20(10):503-511. PubMed ID: 31414725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
    Watanabe K; Shimodaira Y; Takahashi S; Fukuda S; Koizumi S; Matsuhashi T; Iijima K
    Am J Gastroenterol; 2021 Aug; 116(8):1632-1637. PubMed ID: 33989224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
    Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
    Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.